Basilea continues pipeline fill-up by paying Pfizer $37M for Amplyx antifungal

Only two and a half years after Pfizer acquired infectious disease biotech Amplyx for an undisclosed sum, the Big Pharma has sold the lead antifungal asset from that deal to Basilea Pharmaceutica.